Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

Pour a Scotch, we’re talking clinical trials and prediction markets

In last week’s issue of The Cancer Letter, the cover story featured coverage of Kalshi, an online prediction market exchange, launching a pilot program in which one can place bets on both outcomes of trials and FDA decisions.

August 05, 2026

News Analysis

Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake

Prediction market exchanges have allowed the public to bet on the ousting of Nicolás Maduro, the outcome of the Spain v. Argentina World Cup final, and whether Trump will use the word “hippopotamus” in the month of July.

July 31, 2026

Vol.52 No.30

By Sara Willa Ernst

Clinical Trials & Tribulations

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

The recent retraction of the LungTIME-C01 randomized trial evaluating chrono-modulated immunotherapy in non-small cell lung cancer has ignited a vigorous debate regarding the promise of cancer chronotherapy.

July 31, 2026

Vol.52 No.30

By Zachary S. Buchwald and Michael C. Lowe

Cancer Policy

FDA’s OCE publishes three final guidances to increase clinical trial enrollment

FDA’s Oncology Center of Excellence has published three final guidance documents intended to broaden eligibility criteria for participation in clinical trials of oncology drugs.

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to the results of an international phase III clinical trial.

July 31, 2026

Vol.52 No.30

Clinical Roundup

Tecvayli + Talvey, Talvey + pomalidomide show significant survival benefit in earlier-line r/r MM, phase III trial shows

Two drug combinations, Tecvayli (teclistamab-cqyv) + Talvey (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and Talvey + pomalidomide (Pomalyst, sponsored by Bristol Myers Squibb), demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared with investigator’s choice standard of care for adult patients with relapsed or refractory multiple myeloma who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide.

July 24, 2026

Vol.52 No.29

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

YOU MAY BE INTERESTED IN

Pour a Scotch, we’re talking clinical trials and prediction markets

Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

FDA’s OCE publishes three final guidances to increase clinical trial enrollment

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

Tecvayli + Talvey, Talvey + pomalidomide show significant survival benefit in earlier-line r/r MM, phase III trial shows

Renew today!

Subscriber content

Never miss an issue!

Login

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

YOU MAY BE INTERESTED IN

Pour a Scotch, we’re talking clinical trials and prediction markets

Prediction markets now allow betting on clinical trial results, FDA decisionsIt’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

FDA’s OCE publishes three final guidances to increase clinical trial enrollment

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

Tecvayli + Talvey, Talvey + pomalidomide show significant survival benefit in earlier-line r/r MM, phase III trial shows

Never miss an issue!

Login

Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake